PEG-MGF
Also known as: PEGylated MGF, PEGylated Mechano Growth Factor, PEG-MGF E-peptide
4 notable studies · 4 references
TLDR
PEG-MGF is a PEGylated synthetic peptide derived from research on the E-domain of an IGF-1 splice variant associated with mechanical stress, but direct evidence for PEG-MGF itself is extremely limited, controlled human studies are lacking, and findings involving endogenous MGF, IGF-1Ec, gene expression, or unmodified synthetic E-peptides should not automatically be attributed to PEG-MGF.
Research Supports
- MGF E-domain peptides (not PEG-MGF itself) studied for effects on human muscle progenitor-cell proliferation and fusion
- Studied for cell-migration and tissue-repair signaling pathways, including CXCR4/ERK1/2
- Investigated in animal models of cardiac injury for anti-apoptotic, cardioprotective effects
- Explored for neuroprotective effects, including in an ALS mouse model
- Direct published research on the PEGylated research-market product itself remains extremely sparse
Observations Reported in Research
- An MGF E-domain peptide stimulated proliferation and increased fusion potential of human muscle progenitor cells across donor ages (Kandalla et al., 2011)
- A synthetic 24-amino-acid E-domain peptide increased migration of human myogenic precursor cells, apparently independent of the IGF-1 receptor (2007 study)
- A 2014 study found an MGF-derived peptide had no apparent effect on myoblasts or primary muscle stem cells, raising reproducibility concerns (Fornaro et al., 2014)
- An MGF E-domain peptide reduced apoptosis and helped preserve cardiac function after experimental myocardial infarction in mice (2013 study)
- No controlled human trial of PEG-MGF itself was identified
These are brief summaries of what the referenced research examined or reported — not conclusions about safety or effectiveness, and not medical advice. See Notable Studies and Sources & References below for the full context and citations.
At a Glance
Classification: PEGylated synthetic peptide based on the E-domain region associated with an IGF-1 splice variant; experimental research peptide
PEG-MGF may have the messiest evidence inheritance problem we've encountered yet. To understand it, four things need to be separated: IGF-1 ↓ IGF-1 splice variants / pro-IGF-1 isoforms ↓ IGF-1Ec, historically called “Mechano Growth Factor” ↓ Synthetic MGF E-domain peptides ↓ PEGylated synthetic MGF peptide (“PEG-MGF”) These are not interchangeable experimental materials. The research market frequently describes PEG-MGF as though scientists simply discovered a naturally occurring muscle-growth peptide called MGF and then attached PEG to make it last longer. The actual biology is considerably more complicated. A major scientific review noted that while a synthetic peptide corresponding to the unique MGF E-domain has demonstrated biological activity, an analogous free peptide product had not been identified or isolated from cells, conditioned medium, animal tissue, or biological fluids. And direct published research on the PEGylated research-market product itself is extremely sparse.
What Is PEG-MGF?
The human IGF1 gene can produce multiple transcripts through alternative splicing. One transcript commonly called IGF-1Ec contains a distinctive C-terminal E-domain sequence. This transcript became associated with mechanically stimulated skeletal muscle and was given the name Mechano Growth Factor (MGF). That terminology created lasting confusion. The mature IGF-1 portion of the different precursor isoforms is fundamentally related; much of the isoform distinction resides in their E-peptides/propeptide regions. Researchers subsequently synthesized peptides corresponding to portions of the distinctive MGF E-domain and investigated whether these peptides have biological activity of their own. Then the research market introduced PEGylated MGF—a synthetic MGF-related peptide attached to polyethylene glycol to alter stability and pharmacokinetics. That's PEG-MGF. It is therefore several conceptual steps removed from endogenous IGF-1.
What Are Researchers Studying?
Mechanical loading and muscle adaptation
The original MGF story began with observations that mechanical loading changes IGF1 splice-variant expression in skeletal muscle. Animal experiments showed that mechanically overloaded muscle increased expression of a local IGF-1 splice variant associated with satellite-cell activation. Older animals demonstrated a reduced ability to mount this response. This is legitimate and interesting muscle biology. But: Increased expression of an IGF1 splice transcript after exercise does not prove that externally administered PEG-MGF produces muscle hypertrophy. Those are very different propositions.
Muscle progenitor cells
Synthetic MGF E-domain peptides have been studied in human muscle progenitor cells. A 2011 experiment found that an MGF E-peptide stimulated proliferation and increased fusion potential of human muscle progenitor cells from donors of different ages. Earlier work found a synthetic 24-amino-acid E-domain peptide promoted migration of human myogenic precursor cells and suggested an effect independent of the conventional IGF-1 receptor. Those findings support biological activity for certain synthetic E-domain peptides. They do not establish PEG-MGF efficacy in humans.
Muscle hypertrophy
MGF became famous largely because of the hypothesis that mechanically induced IGF1 splicing participates in skeletal-muscle repair and hypertrophy. Mouse experiments provide evidence that IGF-1 E-peptides can influence muscle responses. For example, local expression studies found that IGF-I isoforms containing E-peptides produced muscle hypertrophy under experimental conditions whereas mature IGF-I alone did not produce the same effect. But this involved local gene expression of IGF-I isoforms in mice. It was not a trial of commercial PEG-MGF. That distinction is crucial.
Cell migration and tissue repair
Synthetic MGF E-domain peptides have shown effects on migration of: • Human myogenic precursor cells • Mesenchymal stem cells Research suggests pathways involving extracellular matrix remodeling and CXCR4/ERK1/2 signaling. This has expanded MGF research beyond muscle hypertrophy into broader tissue-repair biology.
Cardiac injury
MGF-related peptides have also been studied after myocardial infarction. In mouse experiments, synthetic MGF E-domain peptides reduced apoptosis and helped preserve aspects of cardiac function following experimental myocardial infarction. Engineered delivery systems have also been developed to provide sustained local release of MGF E-domain peptide to damaged heart tissue. These are interesting regenerative-medicine experiments. They are not evidence that PEG-MGF is a cardiovascular therapy.
Neuroprotection
MGF-related biology has also been investigated in the nervous system. MGF expression has been studied in neurogenic brain regions, and experimental overexpression increased early-stage neurogenesis in aging mice. In an ALS mouse model, MGF-related intervention improved motor-neuron survival and muscle function. Again, these findings involve MGF biology—not necessarily PEG-MGF.
How Does It Work?
This is exactly where Aminodex should not pretend the answer is settled. Several mechanisms have been proposed. IGF-1-related signaling The parent IGF1 gene obviously connects MGF biology to the IGF system. But synthetic E-domain peptides may have biological actions that do not require IGF1R. Cell migration MGF E-peptide has been reported to affect uPA, uPAR, MMP-7, PAI-1, and other pathways involved in cell migration. CXCR4 / ERK1/2 Mesenchymal-stem-cell experiments implicate CXCR4 and ERK signaling in migration induced by MGF E-peptide. Anti-apoptotic activity Cardiac experiments suggest effects on mitochondrial membrane integrity, caspase-3 activation, and cellular survival following stress. PEGylation Attaching polyethylene glycol to peptides can change stability, solubility, proteolytic degradation, distribution, and clearance. But a generic principle of PEGylation does not establish the pharmacokinetics of PEG-MGF in humans.
What Does the Research Show?
Human research
For PEG-MGF itself, controlled human therapeutic evidence is essentially absent. This is the central point. Human evidence exists for: • IGF-1 physiology • Exercise-induced IGF1 gene expression • Human muscle cells studied in vitro • Synthetic MGF E-peptides applied to human-derived cells But none of those is equivalent to humans receiving PEG-MGF in a controlled clinical trial. We should therefore classify PEG-MGF as preclinical.
Animal research
Animal research involving the broader MGF family is considerably richer. Researchers have studied: • Skeletal muscle • Mechanical overload • Aging • Myocardial infarction • ALS models • Neurogenesis • Stem-cell migration But even here, Aminodex needs to label exactly what experimental material was used: endogenous splice variant versus gene overexpression versus synthetic E-domain peptide versus stabilized synthetic analogue versus PEG-MGF. Otherwise we reproduce the same evidence-blending problem we're trying to fix.
In-vitro research
This is where the strongest peptide-specific evidence exists. Synthetic MGF E-domain peptides have demonstrated effects involving: • Human myogenic precursor proliferation • Cell migration • Differentiation • Stem-cell behavior • Apoptosis • Signaling pathways But the literature isn't perfectly consistent. A 2014 study from researchers at Novartis reported that an MGF-derived peptide had no apparent effect on myoblasts or primary muscle stem cells under their experimental conditions. That negative result is very important. It means even the basic cell-biology story isn't universally reproduced.
Notable Studies
Mechano Growth Factor E Peptide (MGF-E), Derived From an Isoform of IGF-1, Activates Human Muscle Progenitor Cells and Induces an Increase in Their Fusion Potential at Different Ages
in-vitroResearchers exposed human muscle progenitor cells from donors of different ages to an MGF E-domain peptide. The peptide stimulated progenitor-cell proliferation and increased subsequent fusion potential, supporting a possible role in muscle repair/regeneration.
Limitations: Cells in culture are not equivalent to systemic peptide administration in humans. The experimental peptide also should not automatically be equated with PEG-MGF.
View publication →A New Pro-Migratory Activity on Human Myogenic Precursor Cells for a Synthetic Peptide Within the E Domain of the Mechano Growth Factor
in-vitroA synthetic 24-amino-acid peptide corresponding to the C-terminal MGF E-domain increased migration of human myogenic precursor cells and altered several migration-related molecular pathways. Results suggested that the response did not require conventional IGF-1 receptor signaling.
Limitations: Synthetic E-domain peptide rather than PEG-MGF; mechanistic/cellular endpoints rather than clinical outcomes.
View publication →Mechano Growth Factor Peptide, the COOH Terminus of Unprocessed Insulin-Like Growth Factor 1, Has No Apparent Effect on Myoblasts or Primary Muscle Stem Cells
in-vitroResearchers attempted to reproduce several biological effects previously attributed to MGF E-peptide. Under their experimental conditions, the peptide showed no apparent effect on proliferation, differentiation, or relevant signaling in the tested muscle-cell systems.
Limitations: Negative cell-culture results do not prove the peptide lacks activity under every biological condition, but they raise an important reproducibility issue.
View publication →The E-Domain Region of Mechano Growth Factor Inhibits Cellular Apoptosis and Preserves Cardiac Function During Myocardial Infarction
animalSynthetic MGF E-domain peptide reduced stress-induced apoptosis in cardiac cells and helped preserve cardiac function after experimental myocardial infarction in mice. The cellular effect occurred without apparent activation of IGF1R.
Limitations: Preclinical cardiac-injury model using a synthetic E-domain peptide—not a human trial and not direct evidence for commercial PEG-MGF. Source evidence type: In vitro + animal — mouse myocardial infarction model. Closest dropdown match: Animal.
View publication →What We Still Don't Know
For PEG-MGF specifically, almost everything clinically important: • Human pharmacokinetics • Human half-life • Bioavailability • Safe exposure • Long-term safety • Whether it increases human muscle mass • Whether it improves recovery • Whether it improves strength • Whether systemic administration reproduces local MGF biology • Whether PEGylation preserves all relevant peptide activity • Whether commercial PEG-MGF has consistent chemical identity • Which receptor mediates E-peptide effects • Whether a naturally occurring free MGF E-peptide exists physiologically • Whether positive cell findings reproduce consistently • Whether effects attributed to MGF actually arise from mature IGF-1 produced from the precursor
Related Compounds
Recent publications
Latest titles from PubMed, not reviewed by Aminodex. Not an endorsement. See all on PubMed ↗
Take the PEG-MGF research with you.
Get the Aminodex PEG-MGF Brief—a concise summary of the research, notable studies, evidence types, limitations, and references.
One-time email. We do not add you to any mailing list.
Sources & References
- Matheny RW Jr, Nindl BC, Adamo ML. Minireview: Mechano-Growth Factor: A Putative Product of IGF-I Gene Expression Involved in Tissue Repair and Regeneration. Endocrinology. 2010.
- Kandalla PK, Goldspink G, Butler-Browne G, Mouly V. Mechano Growth Factor E Peptide (MGF-E), Derived From an Isoform of IGF-1, Activates Human Muscle Progenitor Cells and Induces an Increase in Their Fusion Potential at Different Ages. Mechanisms of Ageing and Development. 2011.
- A New Pro-Migratory Activity on Human Myogenic Precursor Cells for a Synthetic Peptide Within the E Domain of the Mechano Growth Factor.
- Fornaro M, Hinken AC, Needle S, et al. Mechano Growth Factor Peptide, the COOH Terminus of Unprocessed Insulin-Like Growth Factor 1, Has No Apparent Effect on Myoblasts or Primary Muscle Stem Cells. American Journal of Physiology-Endocrinology and Metabolism. 2014.
Supplier Listings
A directory of relevant research suppliers for this compound is not yet available.